Axcella is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for ...
News
- Axcella Announces Upcoming Later-Breaker Presentation at The Digital International Liver ...
- A potential new weapon in the fight against COVID-19: Food coloring
Our biomedical engineering lab has developed a way to potentially neutralize viruses lingering in the air using aerosols of FDA-approved food ...
- Axcella Announces Upcoming Later-Breaker Presentation at The Digital International Liver ...
BUSINESS WIRE)-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on ... Presenter: Stephen A. Harrison, M.D., Medical Director of Pinnacle Clinical Research in San Antonio, TX, visiting professor of ...
- Best colleges in big cities
It's close to downtown San Antonio, a booming city of biotech and ... of the University of Minnesota, students tend to concentrate in biological sciences, ...
- Target, Momenta Pharmaceuticals rise; BioMarin, TJX fall
Johnson & Johnson is buying the biotechnology company for $6.5 billion. Hudson Ltd., up $2.33 to $7.46. Dufry Group AG, the travel retailer's majority ...